Advertisement
New Delhi: Days after the Drugs Controller General of India (DCGI) accorded its approval for Phase 2-3 clinical trials of Bharat Biotech’s Covaxin for children aged between 2-18 years, Niti Aayog Member (Health) Dr. VK Paul on Tuesday informed that the trials will begin in the next 10-12 days
Addressing the media Dr Paul, who is also chairman of the government task force on Covid-19 said, “COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days.”
As part of the second phase of the trial, 525 ‘healthy subjects’ will be administered two doses of the Covaxin vaccine at an interval of 28 days- on day 0 and day 28 through ‘intramuscular route’, as per the release by the Government of India.